Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) – HC Wainwright issued their FY2030 EPS estimates for shares of Can-Fite BioPharma in a note issued to investors on Thursday, July 2nd. HC Wainwright analyst S. Ramakanth expects that the company will post earnings of $0.64 per share for the year. HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Can-Fite BioPharma’s current full-year earnings is ($1.25) per share.
A number of other equities analysts have also weighed in on CANF. Zacks Research upgraded shares of Can-Fite BioPharma to a “hold” rating in a report on Wednesday, May 13th. D. Boral Capital raised Can-Fite BioPharma from a “hold” rating to a “buy” rating in a report on Wednesday, May 13th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Can-Fite BioPharma presently has an average rating of “Moderate Buy” and an average target price of $44.00.
Can-Fite BioPharma Stock Down 15.6%
NYSE:CANF opened at $3.91 on Friday. The company’s 50 day moving average price is $3.20 and its 200-day moving average price is $3.73. Can-Fite BioPharma has a 52 week low of $2.56 and a 52 week high of $21.00. The stock has a market cap of $2.56 million, a price-to-earnings ratio of -2.18 and a beta of 1.11.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Rhumbline Advisers boosted its position in Can-Fite BioPharma by 42.4% in the first quarter. Rhumbline Advisers now owns 38,268 shares of the company’s stock worth $57,000 after purchasing an additional 11,388 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Can-Fite BioPharma in the fourth quarter worth approximately $41,000. Finally, Sabby Management LLC grew its position in Can-Fite BioPharma by 80.3% during the third quarter. Sabby Management LLC now owns 1,406,050 shares of the company’s stock valued at $871,000 after buying an additional 626,306 shares during the period. Institutional investors own 21.00% of the company’s stock.
About Can-Fite BioPharma
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.
The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102).
Featured Stories
- Five stocks we like better than Can-Fite BioPharma
- Why the Comcast Spin-Off Won’t Fix What’s Actually Broken
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
